вторник, 31 января 2017 г.

'The outlier thing didn't work out' - Biotech CEOs reflect...

'The outlier thing didn't work out' - Biotech CEOs reflect...


One of the biggest stories in tech and healthcare over the past year and a half has been the saga of Theranos. The blood-testing company once carried a $9 billion valuation and the promise of running multiple tests on just a single drop of blood.



from Biotech News